Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Mark B. Faries, Eddy C. Hsueh, Xing Ye, et al.
Clinical Cancer Research (2009) Vol. 15, Iss. 22, pp. 7029-7035
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis
Shicheng Su, Qiang Liu, Jingqi Chen, et al.
Cancer Cell (2014) Vol. 25, Iss. 5, pp. 605-620
Open Access | Times Cited: 697
Cutaneous melanoma
Alexander M.M. Eggermont, Alan Spatz, Caroline Robert
The Lancet (2013) Vol. 383, Iss. 9919, pp. 816-827
Closed Access | Times Cited: 504
Exploiting the critical perioperative period to improve long-term cancer outcomes
Maya Horowitz, Elad Neeman, Eran Sharon, et al.
Nature Reviews Clinical Oncology (2015) Vol. 12, Iss. 4, pp. 213-226
Open Access | Times Cited: 429
Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
Alexander M. Lesokhin, Tobias M. Hohl, Shigehisa Kitano, et al.
Cancer Research (2011) Vol. 72, Iss. 4, pp. 876-886
Open Access | Times Cited: 342
The Present and Future of Peptide Vaccines for Cancer
Craig L. Slingluff
The Cancer Journal (2011) Vol. 17, Iss. 5, pp. 343-350
Open Access | Times Cited: 272
Therapeutic cancer vaccines: are we there yet?
Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu, et al.
Immunological Reviews (2010) Vol. 239, Iss. 1, pp. 27-44
Open Access | Times Cited: 272
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley, Michael Borre, Nicholas J. Vogelzang, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 13, pp. 1051-1061
Open Access | Times Cited: 224
Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy
Palash Bhattacharya, Isadore Budnick, Medha Singh, et al.
Journal of Interferon & Cytokine Research (2015) Vol. 35, Iss. 8, pp. 585-599
Open Access | Times Cited: 216
Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
Howard L. Kaufman, Carl E. Ruby, Tasha M. Hughes, et al.
Journal for ImmunoTherapy of Cancer (2014) Vol. 2, Iss. 1
Open Access | Times Cited: 206
Recent Progress in GM-CSF-Based Cancer Immunotherapy
Wan-Lun Yan, Kuan‐Yin Shen, Chun-Yuan Tien, et al.
Immunotherapy (2017) Vol. 9, Iss. 4, pp. 347-360
Closed Access | Times Cited: 171
Eosinophilic Count as a Biomarker for Prognosis of Melanoma Patients and Its Importance in The Response to Immunotherapy
Alvaro Moreira, Waltraud Leisgang, Gerold Schuler, et al.
Immunotherapy (2017) Vol. 9, Iss. 2, pp. 115-121
Closed Access | Times Cited: 131
The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy
April Mengos, Dennis A. Gastineau, Michael P. Gustafson
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 131
Cellular Vaccine Approaches
Dung T. Le, Drew M. Pardoll, Elizabeth M. Jaffee
The Cancer Journal (2010) Vol. 16, Iss. 4, pp. 304-310
Open Access | Times Cited: 127
Cancer Immunotherapy
Robert O. Dillman
Cancer Biotherapy and Radiopharmaceuticals (2011) Vol. 26, Iss. 1, pp. 1-64
Closed Access | Times Cited: 126
A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)
Craig L. Slingluff, Charles Lee, Fengmin Zhao, et al.
Clinical Cancer Research (2013) Vol. 19, Iss. 15, pp. 4228-4238
Open Access | Times Cited: 107
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Jun Yan, Qingnan Zhao, Konrad Gabrusiewicz, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 98
Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
Stefania Cuzzubbo, Sara M. Mangsbo, Divya Nagarajan, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 95
Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
Huashan Liu, Zhenxing Liang, Chi Zhou, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 62
Overview of Cellular Immunotherapy for Patients with Glioblastoma
Élodie Vauléon, Tony Avril, Brigitte Collet, et al.
Journal of Immunology Research (2010) Vol. 2010, Iss. 1
Open Access | Times Cited: 99
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression
Theresa L. Whiteside
Expert Opinion on Biological Therapy (2010) Vol. 10, Iss. 7, pp. 1019-1035
Open Access | Times Cited: 94
GM-CSF as a therapeutic target in inflammatory diseases
Annemarie van Nieuwenhuijze, Marije I. Koenders, Debbie Roeleveld, et al.
Molecular Immunology (2013) Vol. 56, Iss. 4, pp. 675-682
Closed Access | Times Cited: 83
Ex vivogeneration of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer
Inès Dufait, Julia Katharina Schwarze, Thérèse Liechtenstein, et al.
Oncotarget (2015) Vol. 6, Iss. 14, pp. 12369-12382
Open Access | Times Cited: 69
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Caroline Staff, Fariba Mozaffari, Jan‐Erik Frödin, et al.
International Journal of Oncology (2014) Vol. 45, Iss. 3, pp. 1293-1303
Open Access | Times Cited: 68
Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes
Cristina Ghirelli, Fabien Reyal, Marine Jeanmougin, et al.
Cancer Research (2015) Vol. 75, Iss. 14, pp. 2775-2787
Open Access | Times Cited: 57
Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
Jie Liang, Xiao Zhao
Cancer Biology and Medicine (2021) Vol. 18, Iss. 2, pp. 352-371
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top